Bao Le

General Counsel bei SENSEI BIOTHERAPEUTICS, INC.

Health Technology

Profil

Bao Le is currently the Vice President of Regulatory Affairs at Sensei Biotherapeutics, Inc. She started this job in 2021.
Previously, she worked as the Vice President and Head of Global Regulatory Affairs at enGene, Inc.

Aktive Positionen von Bao Le

Unternehmen	Position	Beginn
SENSEI BIOTHERAPEUTICS, INC.	General Counsel	01.06.2021

Alle aktiven Positionen von Bao Le

Ehemalige bekannte Positionen von Bao Le

Unternehmen	Position	Ende
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	General Counsel	-

Sehen Sie sich die Erfahrung von Bao Le im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Bao Le im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
SENSEI BIOTHERAPEUTICS, INC.	Health Technology

Private Unternehmen	1
enGene, Inc. enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.	Health Technology